Table 3.

Sample type and size in selected studies on involvement of P. copri in human diseases.

Condition	Samples	Sample Size*	Abundance in Disease State	Ref
RA vs. OA	Synovial tissue Synovial fluid	Total: 183 patients RA [n = 125] OA [n = 58]	↑	33
RA vs. healthy	Fecal	Total: 31 early RA [n = 17] controls [n = 14]	↑	63
RA vs. healthy	Fecal	Total: 72 Control [n = 32] RA [n = 40]	No difference	35
NORA vs. healthy	Fecal	114 stool samples [RA and control]	↑	43
T2D	Fecal	Total: 80 Healthy [n = 22] T2D [n = 58]	↑	36
T1D	Fecal	Total: 48 Healthy [n = 28] T1D [n = 20]	↑	37
CU	Fecal	Total: 20 Healthy [n = 10] CU [n = 10]	↓	38
Primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD)	Fecal	Total: 106 PSC [n = 11] PSC-IBD [n = 32] UC [n = 32] HCT [n = 31]	↓	91
PD	Fecal	Total: 155 PD [n = 89] Controls [n = 66]	↓	55
NAFLD	Fecal	Total: 124 NAFLD [n = 87] Obese [n = 37]	↑	24
ASD	Fecal	Total: 44 children ASD [n = 23] neurotypical [n = 21]	↓	59
MG	Fecal	Total: 99 pediatrics MG [n = 53] Healthy [n = 46]	↑	95

*In these studies, additional samples were sometimes analyzed; however, the number given only refers to samples in which P. copri was detected.

↑ = increase; ↓ = decrease; Ref = reference.